Sienna Biopharmaceuticals (Sienna Biopharmaceuticals) Total Inventories : $0.00 Mil (As of Sep. 2019)

View and export this data going back to 2017. Start your Free Trial

What is Sienna Biopharmaceuticals Total Inventories?

Sienna Biopharmaceuticals's total inventories for the quarter that ended in Sep. 2019 was $0.00 Mil. Sienna Biopharmaceuticals's average total inventories from the quarter that ended in Jun. 2019 to the quarter that ended in Sep. 2019 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Sienna Biopharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Sep. 2019 was $-0.29.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Sienna Biopharmaceuticals Total Inventories Historical Data

The historical data trend for Sienna Biopharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sienna Biopharmaceuticals Total Inventories Chart

Sienna Biopharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Total Inventories

Sienna Biopharmaceuticals Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Total Inventories	Get a 7-Day Free Trial											-	-	-	-	-

Sienna Biopharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Sienna Biopharmaceuticals (OTCPK:SNNAQ) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Sienna Biopharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2019 is

	Net-Net Working Capital Per Share (Q: Sep. 2019 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(11.332	+	0.75 * 0	+	0.5 * 0	-	20.391
-	0	-	0)	/	30.765
=	-0.29

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Sienna Biopharmaceuticals's Days Inventory for the three months ended in Sep. 2019 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2019 )	/	Cost of Goods Sold (Q: Sep. 2019 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Sienna Biopharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2019 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Sep. 2019 )	/	Average Total Inventories (Q: Sep. 2019 )
	=	0	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Sienna Biopharmaceuticals's Inventory to Revenue for the quarter that ended in Sep. 2019 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Sep. 2019 )	/	Revenue (Q: Sep. 2019 )
	=	0	/	0
	=

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Sienna Biopharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Sienna Biopharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Sienna Biopharmaceuticals (Sienna Biopharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sienna Biopharmaceuticals Inc (OTCPK:SNNAQ) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

30699 Russell Ranch Road, Suite 140, Westlake Village, CA, USA, 91362

Website

http://www.SiennaBio.com

Sienna Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development, and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The objective is to develop multi-asset pipeline of topical therapies that enhance the health, appearance, and quality of life of dermatology patients. The product portfolio includes SNA-120, SNA-125, and SNA-001.

Executives

Alexander Azoy	officer: Chief Financial Officer	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Timothy K. Andrews	officer: General Counsel & Secretary	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Iii Frederick Beddingfield	director, officer: President & CEO	C/O KYTHERA BIOPHARMACEUTICALS, INC. 27200 WEST AGOURA ROAD, SUITE 200 CALABASAS CA 91301
Paul F. Lizzul	officer: Chief Medical Officer	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Diane Stroehmann	officer: See Remarks	30699 RUSSELL RANCH ROAD SUITE 140 WESTLAKE VILLAGE CA 91362
Dennis M Fenton	director
Todd Harris	director	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Kristina Burow	director, 10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Robert J More	director	680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001
James M. Hindman	director	2525 DUPONT DRIVE, IRVINE CA 92612
Keith R Leonard	director	ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Arch Venture Partners Viii, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund Viii Overage, L.p.	10 percent owner	C/O ARCH VENTURE PARTNERS VIII, LLC, 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund X Overage, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners X Overage, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631